BridgeBio Pharma Inc (BBIO)
NASDAQ
News
Market Data
Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
The current BBIO market cap is 6.65B. The company's latest EPS is USD -3.4034 and P/E is -10.46.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 4.09M | 1.75M | 211.12M | 2.17M | 2.73M |
| Operating Income | -157.69M | -177.42M | 343k | -56.9M | -191.75M |
| Net Income | -177M | -168.15M | -35.22M | -73.46M | -162.04M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 40.56M | 8.25M | 69.72M | 77.65M | 9.3M |
| Operating Income | -287.11M | -474.48M | -546.72M | -512.2M | -607.37M |
| Net Income | -260.59M | -448.72M | -562.54M | -481.18M | -643.2M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 655.01M | 546.38M | 849.33M | 794.38M | 664.98M |
| Total Liabilities | 1.85B | 1.89B | 1.89B | 1.88B | 1.88B |
| Total Equity | -1.2B | -1.34B | -1.04B | -1.08B | -1.22B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 631.68M | 703.59M | 1.01B | 623.04M | 546.38M |
| Total Liabilities | 155.7M | 595.7M | 1.88B | 1.87B | 1.89B |
| Total Equity | 473.73M | 106.26M | -867M | -1.24B | -1.34B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -402.9M | -527.72M | -219.54M | -144.83M | -325.4M |
| Investing | 54.1M | 54.03M | 22.75M | 25.79M | 64.02M |
| Financing | 456.06M | 451.54M | 279.55M | 273.82M | 274.53M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -253.59M | -399.71M | -497.93M | -419.49M | -527.72M |
| Investing | -217.25M | -52.99M | -200.83M | 453.15M | 54.03M |
| Financing | 398.79M | 447.19M | 736.45M | -13.13M | 451.54M |
| Market Cap | 6.65B |
| Price to Earnings Ratio | -10.46 |
| Price to Sales Ratio | 723.58 |
| Price to Cash Ratio | 17.9 |
| Price to Book Ratio | -5.01 |
| Dividend Yield | - |
| Shares Outstanding | 188.99M |
| Average Volume (1 week) | 5.37M |
| Average Volume (1 Month) | 2.53M |
| 52 Week Change | -7.35% |
| 52 Week High | 41.04 |
| 52 Week Low | 21.62 |
| Spread (Intraday) | 0.07 (0.2%) |
| Company Name | BridgeBio Pharma Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.bridgebio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
